Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
about
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataPediatric Statin Administration: Navigating a Frontier with Limited DataMembrane transporters in drug developmentSimultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic modelInvestigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.Understanding and preventing drug-drug and drug-gene interactions.Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.Impact of OATP transporters on pharmacokinetics.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers.Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae).Use of in-silico assays to characterize the ADMET profile and identify potential therapeutic targets of fusarochromanone, a novel anti-cancer agentTransporters and their impact on drug disposition.Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.Rosuvastatin for the treatment of hypercholesterolemia.No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Lipid-lowering effects of statins: a comparative review.Role of P-glycoprotein in statin drug interactions.Drug-drug interaction pattern recognition.Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.Transporter-mediated uptake into cellular compartments.Role of OATP transporters in the disposition of drugs.New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.Efficacy and safety of rosuvastatin in the management of dyslipidemiaEffects of drug transporters on volume of distribution.Predicting drug-drug interactions: an FDA perspectiveHepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytesHepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineDoes simvastatin cause more myotoxicity compared with other statins?
P2860
Q27009128-2EC8B768-C746-4C74-82EA-4F4BF6607968Q28068014-171D8F48-19CA-4FD9-84BE-9C9D21D06232Q29616802-BF97DB9B-0924-4711-ADE6-F013D89EE882Q30511951-D40C8750-6ADB-484C-9B67-F7BFAADE1AFCQ33581531-4703E690-ACBA-447C-8CC0-0CF15FD8408EQ34023028-598E5584-D1D1-4DF0-813E-3B8A927CD312Q34094825-E55B6373-DD34-4EE2-BD3A-95E69396D204Q34415944-0AA25237-8DE1-4CD4-8F53-98518A6C41E6Q34599850-469D7367-A50C-4E89-A02B-B9C4D6CC7D15Q34612244-BD93739B-92EE-43DF-A5E7-A88CCD887A41Q34871636-D2DC3F10-9441-4CAE-918B-2552E3C2ABB6Q35080119-B1102C5C-2296-45A6-95E1-985B7E926807Q35088420-20F32E87-CE90-4B3D-93D0-4F3D028720BBQ35183649-2F00F9D6-FB63-47FD-9377-2C6EEF898512Q35270890-EB89B541-2AEA-4321-881B-6107F3A3D83EQ35430039-EDCB0E47-2D36-41DA-8003-C0D7592612A2Q35729725-95C6E341-D8A8-4D0D-866A-E2C43263698AQ36123304-5A56B03F-F828-4915-B6B3-84258DE47DF8Q36163801-1F860F30-B30A-439D-B714-A7C31C44B679Q36188328-02E80343-C6EF-4952-9A8A-8505ECF84301Q36536042-FF4481E9-03B6-43E5-8D69-79F09C3BF135Q36544966-C4BAAE33-1BB9-4D15-88C4-B621FA644F34Q36573878-FBBBCB63-6F22-44ED-BB4E-EDD1C694E31DQ36634221-F9AC00A4-E52E-4BF8-9E60-0D4B7B8F0784Q36649880-599DE0E3-32F1-449A-8093-04A3F9A4B49BQ36687277-5D536AE9-8BAF-4BA2-AD50-8D4F3736927DQ36742673-A7C0641B-5B99-49C6-8393-F045D75BE849Q36752063-D17FD0A6-F426-4CD2-8512-056355AA48C6Q36985076-3280D008-336C-4EF7-90FA-1F236C926500Q37074085-D54F92D0-1F56-4EC3-BDDA-7A98E89077CFQ37124261-BDAAB7F5-1EB8-4997-B67A-1C2DCC3B34CFQ37167517-7495F284-63FC-4C88-94E6-B7752FF017FBQ37214523-C4FEEF2F-95E4-463D-B921-39ACDD718EE4Q37214533-5F4CE5B1-61D6-4F76-ADF7-710133A33943Q37331801-4BC8F069-3DCE-4F98-AEDD-35EF51225874Q37331821-48A1E242-8E6F-4861-A3AC-7FE74797B664Q37392745-A45D2597-D946-437C-96F7-C37856FC0FE5Q37469352-A1629C20-F4D3-498F-A368-54D1D38D40D1Q37470663-4973F31F-FB4A-4BE9-B2FA-BFAC08344C10Q37634190-2BBF81C5-FD6C-4D24-B483-F6A09FE12468
P2860
Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@ast
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@en
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@nl
type
label
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@ast
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@en
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@nl
prefLabel
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@ast
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@en
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@nl
P2093
P1476
Rosuvastatin pharmacokinetics ...... egimen including cyclosporine.
@en
P2093
Amy S Windass
Colin D A Brown
Dennis W Schneck
John A Jarcho
Patrick D Mitchell
Paul D Martin
Steven G Simonson
P304
P356
10.1016/J.CLPT.2004.03.010
P407
P577
2004-08-01T00:00:00Z